QA: CytomX Therapeutics Inc. in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001501989_2023_CytomX_Therapeutics_Inc.pdf

Logs

Graph

Absolute values for 0001501989, CytomX Therapeutics Inc.

  xvar xval
0 AssetsCurrent 237,102,000
1 IntangibleAssetsNetIncludingGoodwill 949,000
2 PropertyPlantAndEquipmentNet 5,072,000
3 remainder_Assets 17,768,000
4 LiabilitiesCurrent 152,608,000
5 LiabilitiesNoncurrent 194,034,000
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 42,849,000
9 ResearchAndDevelopmentExpense 111,649,000
10 remainder_Expenses 0
11 remainder_Revenues 53,163,000
12 remainder_NetIncome 2,018,000
13 remainder_ComprehensiveNetIncome 252,000
  yvar yval
0 Assets 260,891,000
1 Liabilities 346,642,000
2 Expenses 154,498,000
3 Revenues 53,163,000
4 StockholdersEquity -85,751,000
5 NetIncome -99,317,000
6 ComprehensiveNetIncome -99,191,000
7 BaseVar 408,732,000
8 EconomicCapitalRatio -0.812

Edgar->Model Mapping

Feature Distribution

Change over Time